Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancer

- LP-184 preclinical studies reinforce the drug compound's potential to effectively cross the blood-brain barrier with significant potency - Continued progress in advancing glioblastoma indication towards IND enabling studies - Multiple collaborations underway for GBM and potentially other CNS (Central Nervous System) & Brain cancers

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here